Ocugen Inc (OCGN) gains 0.4610% for June 17

Equities Staff  |

Ocugen Inc (NASDAQ: OCGN) shares gained 0.4610% to end trading Thursday at $6.54 per share - a net change of $0.03. Shares traded between $6.80 and $6.40 throughout the day.

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Visit Ocugen Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Ocugen Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Ocugen Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content